Compare Stocks: ANVS, ALXO, ADAG, and NKTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.97 -8.0%	$3.64	$1.30 ▼ $4.85	$213.35M	0.56	200,452 shs	207,966 shs
ALXO ALX Oncology	$1.47 -8.1%	$1.95	$1.05 ▼ $2.66	$221.24M	0.39	902,483 shs	1.28 million shs
ANVS Annovis Bio	$1.28 +1.2%	$1.61	$1.04 ▼ $5.50	$53.78M	1.24	1.31 million shs	1.14 million shs
NKTX Nkarta	$2.76 -6.4%	$2.58	$1.70 ▼ $3.72	$211.29M	0.97	539,224 shs	1.09 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	-8.05%	-6.31%	-23.85%	-27.91%	+44.88%
ALXO ALX Oncology	-8.13%	-16.48%	-26.13%	-17.88%	+16.67%
ANVS Annovis Bio	+0.79%	+18.60%	-26.93%	-22.96%	-42.70%
NKTX Nkarta	-6.44%	-3.83%	+6.56%	-0.72%	+35.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAG Adagene	$2.97 -8.0%	$3.64	$1.30 ▼ $4.85	$213.35M	0.56	200,452 shs	207,966 shs
ALXO ALX Oncology	$1.47 -8.1%	$1.95	$1.05 ▼ $2.66	$221.24M	0.39	902,483 shs	1.28 million shs
ANVS Annovis Bio	$1.28 +1.2%	$1.61	$1.04 ▼ $5.50	$53.78M	1.24	1.31 million shs	1.14 million shs
NKTX Nkarta	$2.76 -6.4%	$2.58	$1.70 ▼ $3.72	$211.29M	0.97	539,224 shs	1.09 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAG Adagene	-8.05%	-6.31%	-23.85%	-27.91%	+44.88%
ALXO ALX Oncology	-8.13%	-16.48%	-26.13%	-17.88%	+16.67%
ANVS Annovis Bio	+0.79%	+18.60%	-26.93%	-22.96%	-42.70%
NKTX Nkarta	-6.44%	-3.83%	+6.56%	-0.72%	+35.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAG Adagene	2.80	Moderate Buy	$8.67	191.81% Upside
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	212.93% Upside
ANVS Annovis Bio	2.25	Hold	$12.00	841.18% Upside
NKTX Nkarta	2.86	Moderate Buy	$11.20	305.80% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, ADAG, and NKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	NKTX Nkarta	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/17/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/14/2026	ADAG Adagene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/10/2026	ADAG Adagene	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
9/2/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00 ➝ $7.00
8/19/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/18/2026	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$11.00 ➝ $10.00
8/11/2026	NKTX Nkarta	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00
8/5/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAG Adagene	$9.29M	21.11	N/A	N/A	$0.75 per share	3.96
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.48 per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.64 per share	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	$4.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAG Adagene	-$17.61M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
ANVS Annovis Bio	-$28.85M	-$1.79	N/A	N/A	N/A	N/A	-685.98%	-258.77%	11/11/2026 (Estimated)
NKTX Nkarta	-$104.08M	-$1.57	N/A	N/A	N/A	N/A	-39.64%	-30.45%	11/10/2026 (Estimated)

Latest ANVS, ALXO, ADAG, and NKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ANVS Annovis Bio	-$0.4533	-$0.40	+$0.0533	-$0.40	N/A	N/A
8/10/2026	Q2 2026	NKTX Nkarta	-$0.3603	-$0.54	-$0.1797	-$0.54	N/A	N/A
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAG Adagene	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAG Adagene	0.01	5.02	3.07
ALXO ALX Oncology	0.07	9.71	9.71
ANVS Annovis Bio	N/A	3.47	3.47
NKTX Nkarta	N/A	7.98	7.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAG Adagene	9.51%
ALXO ALX Oncology	97.97%
ANVS Annovis Bio	15.83%
NKTX Nkarta	80.54%

Insider Ownership

Company	Insider Ownership
ADAG Adagene	21.20%
ALXO ALX Oncology	12.40%
ANVS Annovis Bio	15.92%
NKTX Nkarta	9.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAG Adagene	128	66.05 million	52.05 million	Not Optionable
ALXO ALX Oncology	48	138.28 million	121.13 million	Optionable
ANVS Annovis Bio	7	42.68 million	35.89 million	Optionable
NKTX Nkarta	106	71.63 million	64.61 million	Optionable

ANVS, ALXO, ADAG, and NKTX Headlines

Recent News About These Companies

Nkarta to Participate in September Investor Conferences

September 10, 2026 | globenewswire.com

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

September 8, 2026 | globenewswire.com

6,300,212 Shares in Nkarta, Inc. $NKTX Acquired by BlackRock Inc.

September 4, 2026 | marketbeat.com

Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 3, 2026 | marketbeat.com

Alyeska Investment Group L.P. Sells 1,600,000 Shares of Nkarta, Inc. $NKTX

September 2, 2026 | marketbeat.com

AWM Investment Company Inc. Takes Position in Nkarta, Inc. $NKTX

August 26, 2026 | marketbeat.com

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

August 10, 2026 | markets.businessinsider.com

Nkarta Reports Continued Enrollment in Ntrust Autoimmune Trials and $243.2 Million Cash Position, Reaffirms Runway Into 2029

August 10, 2026 | quiverquant.comQ

Nkarta (NKTX) Stock Forecast & Price Target

August 7, 2026 | investing.com

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

July 23, 2026 | globenewswire.com

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 26, 2026 | globenewswire.com

Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay

June 11, 2026 | tipranks.com

Nkarta Inc Ordinary Shares NKTX

May 16, 2026 | morningstar.comM

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation

May 14, 2026 | finance.yahoo.com

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

May 12, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF)

April 23, 2026 | theglobeandmail.com

NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program

April 17, 2026 | zacks.com

Nkarta rises on FDA agreement for amended trial protocol

April 16, 2026 | msn.com

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

April 15, 2026 | globenewswire.com

Nkarta to Participate in Needham Virtual Healthcare Conference

April 9, 2026 | globenewswire.com

Nkarta Launches $100 Million At-the-Market Stock Offering

March 26, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, ADAG, and NKTX Company Descriptions

Adagene NASDAQ:ADAG

$2.97 -0.26 (-8.05%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.98 +0.01 (+0.34%)

As of 09/23/2026 07:30 PM Eastern

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

ALX Oncology NASDAQ:ALXO

$1.47 -0.13 (-8.13%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.45 -0.02 (-1.56%)

As of 04:01 AM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Annovis Bio NYSE:ANVS

$1.27 +0.02 (+1.19%)

Closing price 09/23/2026 03:59 PM Eastern

Extended Trading

$1.33 +0.06 (+4.63%)

As of 05:00 AM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Nkarta NASDAQ:NKTX

$2.76 -0.19 (-6.44%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.74 -0.02 (-0.87%)

As of 04:01 AM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, ADAG, and NKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANVS, ALXO, ADAG, and NKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANVS, ALXO, ADAG, and NKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, ADAG, and NKTX Company Descriptions

Adagene NASDAQ:ADAG

ALX Oncology NASDAQ:ALXO

Annovis Bio NYSE:ANVS

Nkarta NASDAQ:NKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, ADAG, and NKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANVS, ALXO, ADAG, and NKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANVS, ALXO, ADAG, and NKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, ADAG, and NKTX Company Descriptions

Adagene NASDAQ:ADAG

ALX Oncology NASDAQ:ALXO

Annovis Bio NYSE:ANVS

Nkarta NASDAQ:NKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools